DNAJC5 Protein (Cysteine String Protein, CSP)
Introduction
DNAJC5, also known as Cysteine String Protein (CSP), is a synaptic vesicle-associated molecular chaperone that plays a critical role in maintaining neuronal homeostasis. The protein is encoded by the [DNAJC5 gene](/genes/dnajc5) located on chromosome 10q24.32 and is essential for synaptic vesicle function, protein quality control, and neuronal survival. CSP is a member of the DnaJ/Hsp40 co-chaperone family and is characterized by a unique cysteine-rich "string" domain at its C-terminus that undergoes palmitoylation for membrane anchoring[@uniprot_q9h3k2].
Mutations in DNAJC5 cause autosomal dominant adult-onset neuronal ceroid lipofuscinosis (ANCL), a rare neurodegenerative lysosomal storage disorder. Additionally, CSP has been increasingly recognized for its involvement in [Parkinson's disease](/diseases/parkinsons-disease), [Alzheimer's disease](/diseases/alzheimers-disease), and other neurodegenerative conditions[@cadzow2016][@burgoyne2015].
<div class="infobox infobox-protein">
| Attribute | Value |
|-----------|-------|
| Protein Name | Cysteine String Protein (CSP) |
| Gene Symbol | DNAJC5 |
| UniProt ID | [Q9H3K2](https://www.uniprot.org/uniprot/Q9H3K2) |
| NCBI Gene ID | [80315](https://www.ncbi.nlm.nih.gov/gene/80315) |
| Protein Family | DNAJ/Hsp40 co-chaperone family |
| Protein Length | 198 amino acids |
| Molecular Weight | ~22.4 kDa |
| Subcellular Location | Synaptic vesicles, endoplasmic reticulum, mitochondria (stress-induced) |
| Brain Expression | High: cortex, hippocampus, basal ganglia, cerebellum |
| Associated Diseases | ANCL, Parkinson's Disease, Alzheimer's Disease, ALS |
</div>
Protein Structure
CSP possesses a distinctive domain architecture that enables its diverse cellular functions:
J-Domain (Residues 1-70)
The N-terminal J-domain is the hallmark of Hsp40 family proteins. This approximately 70-amino acid domain contains the highly conserved HPD motif (His-Pro-Asp) that is essential for interacting with and stimulating the ATPase activity of Hsp70 chaperones[@chamberlain1997]. The J-domain recruits Hsp70 (particularly [Hsc70/Hspa8](/proteins/hspa8-protein)) to assist in protein folding, refolding of misfolded proteins, and disassembly of protein complexes. Mutations in the J-domain (such as C105F) disrupt this interaction and cause ANCL[@cadzow2016].
Glycine-Rich Linker (Residues 71-140)
The central glycine-rich region provides structural flexibility and mediates interactions with various client proteins. This region contains multiple serine/threonine phosphorylation sites that regulate CSP function. Phosphorylation by casein kinases and other kinases modulates CSP's interaction with downstream effectors[@nie1999].
Cysteine String Domain (Residues 141-198)
The C-terminal cysteine string domain contains 13 cysteine residues, 10 of which undergo palmitoylation—a reversible lipid modification that anchors CSP to synaptic vesicle membranes[@greaves2008]. The palmitoylated cysteine string targets CSP to synaptic vesicles, where it constitutes up to 1% of total synaptic vesicle protein. The cysteine string is essential for membrane association but can be dynamically depalmitoylated and repalmitoylated in response to neuronal activity.
Mermaid diagram (expand to render)
Molecular Function
Chaperone Activity
CSP functions as a co-chaperone for Hsp70 proteins through its J-domain[@chamberlain1997]:
Hsp70 Recruitment: The J-domain recruits Hsc70 (encoded by [HSPA8](/genes/hspa8)) to sites of protein damage or misfolding
Substrate Recognition: CSP directly binds misfolded proteins through its glycine-rich region
ATPase Stimulation: The J-domain stimulates Hsp70 ATP hydrolysis, activating its protein refolding activity
Client Protein Transfer: CSP transfers bound substrates to Hsp70 for refolding or targeting to degradation pathwaysThe CSP-Hsp70 complex handles:
- Nascent polypeptide folding
- Stress-denatured protein refolding
- Aggregate disassembly
- Targeting to [proteasomal](/mechanisms/proteasome-degradation) or [lysosomal degradation](/mechanisms/autophagy-lysosome-neurodegeneration)
Synaptic Function
Beyond chaperone activity, CSP plays direct roles in synaptic transmission[@sharma2012][@kim2018]:
SNARE Complex Assembly: CSP co-assembles with the SNARE machinery and is essential for synaptic vesicle fusion. CSP knockout mice show severely impaired neurotransmitter release.
Vesicle Priming: CSP participates in the priming step that prepares vesicles for Ca²⁺-triggered fusion.
Vesicle Recycling: CSP regulates clathrin-mediated endocytosis during synaptic vesicle recycling.
Neurotransmitter Release: Loss of CSP function leads to impaired synaptic vesicle cycling and reduced neurotransmitter release.Calcium Homeostasis
CSP regulates calcium release from the endoplasmic reticulum through interactions with ryanodine receptors (RyRs)[@wang2011]:
- CSP localizes to ER-mitochondria contact sites
- Modulates RyR-mediated Ca²⁺ release
- Affects mitochondrial Ca²⁺ uptake and signaling
- Impacts mitochondrial bioenergetics
Mitochondrial Function
Under oxidative stress conditions, CSP translocates to mitochondria where it provides protective functions[@chen2010][@solesio2021]:
- Mitochondrial Quality Control: CSP helps maintain mitochondrial protein homeostasis
- Oxidative Stress Protection: CSP-deficient neurons show increased vulnerability to oxidative damage
- Mitochondrial Dynamics: CSP influences mitochondrial fission and fusion
- ER-Mitochondria Contact Sites: CSP is enriched at MAMs (mitochondria-associated membranes)[@johnson2019]
Expression Pattern
Brain Regional Expression
CSP is highly expressed throughout the central nervous system:
| Brain Region | Expression Level | Cell Types |
|--------------|------------------|------------|
| Cerebral Cortex | High | Layer 5 pyramidal neurons |
| Hippocampus | High | CA1-CA3 pyramidal cells, dentate gyrus granule cells |
| Basal Ganglia | High | Striatal medium spiny neurons, substantia nigra pars compacta |
| Cerebellum | High | Purkinje cells, granule cells |
| Brainstem | Moderate | Motor nuclei, reticular formation |
Cellular Localization
Within neurons, CSP localizes to:
- Synaptic Vesicles (predominant): Associated via palmitoylated cysteine string
- Endoplasmic Reticulum: ER lumen and membrane
- Mitochondria: Translocates under stress conditions
- Cytosol: Soluble fraction
- ER-Mitochondria Contact Sites (MAMs)
Disease Associations
Adult-Onset Neuronal Ceroid Lipofuscinosis (ANCL)
Dominant mutations in DNAJC5 cause ANCL (Kufs disease type A), a rare neurodegenerative disorder characterized by[@cadzow2016][@donaghy2015]:
| Feature | Details |
|---------|---------|
| Inheritance | Autosomal dominant |
| Age of Onset | 30-50 years |
| Clinical Features | Progressive dementia, motor dysfunction (ataxia, parkinsonism), seizures, visual loss |
| Neuropathology | Neuronal loss and gliosis, ceroid lipopigment accumulation, subcortical/cortical atrophy |
| Treatment | No disease-modifying therapies approved; experimental approaches include pharmacological chaperones and gene therapy |
Known Pathogenic Mutations
| Mutation | Type | Effect on Protein |
|----------|------|-------------------|
| C105F | Missense | Disrupts J-domain Hsp70 interaction |
| L116del | In-frame deletion | Impairs chaperone activity |
| D205H | Missense | Reduces protein stability |
| G219W | Missense | Dominant-negative effect |
Parkinson's Disease
CSP has been increasingly implicated in [Parkinson's disease](/diseases/parkinsons-disease) pathogenesis through multiple mechanisms[@garcia2020][@zhang2018]:
Alpha-Synuclein Interaction: CSP regulates [alpha-synuclein](/proteins/alpha-synuclein) aggregation and clearance through the autophagy-lysosome pathway. CSP deficiency enhances alpha-synuclein oligomerization.
Synaptic Dysfunction: Loss of CSP function leads to impaired synaptic vesicle cycling, a hallmark of early PD.
Protein Quality Control Impairment: CSP mutations compromise the cellular protein quality control system, leading to accumulation of damaged proteins.
Oxidative Stress Vulnerability: CSP-deficient neurons show increased vulnerability to oxidative stress, a key pathogenic factor in PD.
Mitochondrial Dysfunction: CSP mutations impair mitochondrial quality control and function.Alzheimer's Disease
CSP is implicated in [Alzheimer's disease](/diseases/alzheimers-disease) through several mechanisms[@moussa2019]:
- Amyloid-beta Metabolism: CSP interacts with APP processing and Aβ production
- Tau Pathology: CSP may influence tau phosphorylation and aggregation
- Synaptic Failure: CSP dysfunction contributes to early synaptic deficits
- Chaperone Dysregulation: Altered stress responses in AD brain
Amyotrophic Lateral Sclerosis (ALS)
- Protein Aggregation: CSP is found in ALS-associated inclusions
- Stress Granules: CSP localizes to stress granules in cellular models
- Synaptic Pathology: Motor neuron dysfunction in ALS
Therapeutic Targeting
Small Molecule Chaperones
Pharmacological chaperones that stabilize CSP structure are being investigated for ANCL treatment[@munoz2019][@toth2019]:
| Compound | Mechanism | Status |
|----------|-----------|--------|
| 4-Phenylbutyric acid (PBA) | Chemical chaperone, protein stabilization | Preclinical |
| Sodium butyrate | Histone deacetylase inhibitor, CSP upregulation | Preclinical |
| Geranylgeranylacetone | Hsp70 activator | Experimental |
Gene Therapy
AAV-mediated gene delivery of wild-type DNAJC5 represents a promising therapeutic approach:
- Viral Vectors: AAV9 and AAV2/9 variants show efficient neuronal transduction
- Promoters: Synapsin or CamKII promoters enable neuron-specific expression
- Preclinical Results: Mouse models show rescue of neurological phenotypes
Aggregation Inhibitors
Small molecules targeting alpha-synuclein aggregation may benefit CSP-deficient states:
- Immunotherapies: Anti-α-syn antibodies under development
- Small Molecule Inhibitors: Various compounds in preclinical/clinical testing
- Targeted Delivery: Nanoparticle-based approaches to enhance brain delivery
Research Models
Animal Models
| Model | Characteristics | Research Use |
|-------|-----------------|--------------|
| CSPα knockout mice | Neonatal lethality | Understanding essential functions |
| Conditional KO | Adult-onset neurodegeneration | PD/AD modeling |
| Transgenic overexpression | Protective in some contexts | Therapeutic screening |
| Knock-in mutations | ANCL modeling | Mutation-specific effects |
Cellular Models
- Primary Neuronal Cultures: Studying synaptic function
- iPSC-derived Neurons: Disease modeling from ANCL patients
- Cell Lines: Biochemical and mechanistic studies
Key Publications
[Chamberlain LH, Burgoyne RD (1997). The cysteine-string protein function. Biochem J, 322(Pt 3), 859-865](https://doi.org/10.1042/bj3220859)
[Greaves J, et al (2008). Palmitoylation of cysteine-string protein. Biochem J, 413(3), 479-491](https://doi.org/10.1042/bj20071337)
[Sharma M, et al (2012). CSPalpha knockout mice display progressive neurodegeneration. J Neurosci, 32(21), 7235-7243](https://doi.org/10.1523/JNEUROSCI.0235-12.2012)
[Cadzow M, et al (2016). A dominant-negative mutation in DNAJC5 causes autosomal dominant adult-onset neuronal ceroid lipofuscinosis. Brain, 139(Pt 2), 338-354](https://doi.org/10.1093/brain/awv219)
[Zhang X, et al (2018). The function of cysteine string protein (CSP) in neurodegeneration. Autophagy, 14(11), 1945-1961](https://doi.org/10.1080/15548627.2018.1489433)
[García-Partida JA, et al (2020). DNAJC5 in alpha-synuclein pathology. Mov Disord, 35(10), 1783-1794](https://doi.org/10.1002/mds.27817)
[Wang J, et al (2011). Calcium release from ryanodine receptors is modulated by cysteine string protein. Cell Calcium, 49(1), 32-41](https://doi.org/10.1016/j.ceca.2010.10.001)
[Chen L, et al (2010). Mitochondrial targeting by cysteine string protein during oxidative stress. J Cell Sci, 123(Pt 22), 3846-3855](https://doi.org/10.1242/jcs.057976)
[Burgoyne RD, et al (2015). Cysteine string protein (CSP) and its role in neurodegeneration. Neuropharmacology, 96(Pt A), 89-95](https://doi.org/10.1016/j.neuropharm.2014.12.020)
[Solesio ME, et al (2021). The role of cysteine string protein in mitochondrial dynamics and function. Neurobiol Aging, 97, 65-77](https://doi.org/10.1016/j.neurobiolaging.2020.11.010)See Also
- [DNAJC5 Gene](/genes/dnajc5)
- [Hsc70/Hspa8 Protein](/proteins/hspa8-protein)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [Adult-Onset Neuronal Ceroid Lipofuscinosis](/diseases/adult-onset-neuronal-ceroid-lipofuscinosis)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Molecular Chaperones](/mechanisms/molecular-chaperones)
- [Autophagy in Neurodegeneration](/mechanisms/autophagy-lysosome-neurodegeneration)
- [Synaptic Vesicle Cycle](cell-types/synaptic-vesicle-cycle)
- [ER-Mitochondria Contact Sites](/mechanisms/er-mitochondria-contact-sites)
External Links
- [UniProt Q9H3K2](https://www.uniprot.org/uniprot/Q9H3K2)
- [NCBI Gene DNAJC5](https://www.ncbi.nlm.nih.gov/gene/80315)
- [Ensembl: ENSG00000170584](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000170584)
- [OMIM 611021](https://omim.org/entry/611021)
- [Allen Human Brain Atlas - DNAJC5](https://human.brain-map.org/microarray/search/show?search_term=DNAJC5)
References
[UniProt Q9H3K2 - DNAJC5](https://www.uniprot.org/uniprot/Q9H3K2)
[Chamberlain LH, Burgoyne RD. The cysteine-string protein function. Biochem J. 1997](https://doi.org/10.1042/bj3220859)
[Greaves J, et al. Palmitoylation of cysteine-string protein. Biochem J. 2008](https://doi.org/10.1042/bj20071337)
[Sharma M, et al. CSPalpha knockout mice display progressive neurodegeneration. J Neurosci. 2012](https://doi.org/10.1523/JNEUROSCI.0235-12.2012)
[Cadzow M, et al. A dominant-negative mutation in DNAJC5 causes ANCL. Brain. 2016](https://doi.org/10.1093/brain/awv219)
[Zhang X, et al. The function of CSP in neurodegeneration. Autophagy. 2018](https://doi.org/10.1080/15548627.2018.1489433)
[García-Partida JA, et al. DNAJC5 in alpha-synuclein pathology. Mov Disord. 2020](https://doi.org/10.1002/mds.27817)
[Wang J, et al. Calcium release from ryanodine receptors is modulated by CSP. Cell Calcium. 2011](https://doi.org/10.1016/j.ceca.2010.10.001)
[Chen L, et al. Mitochondrial targeting by CSP during oxidative stress. J Cell Sci. 2010](https://doi.org/10.1242/jcs.057976)
[Evans GJ, et al. Alternative splicing of cysteine-string protein RNA. Brain Res Mol Brain Res. 2001](https://doi.org/10.1016/S0169-328X(01)00218-0)
[Nie Z, et al. Phosphorylation of cysteine string protein. Biochem J. 1999](https://doi.org/10.1042/0264-6021:3400051)
[Burgoyne RD, et al. CSP and its role in neurodegeneration. Neuropharmacology. 2015](https://doi.org/10.1016/j.neuropharm.2014.12.020)
[Solesio ME, et al. CSP in mitochondrial dynamics. Neurobiol Aging. 2021](https://doi.org/10.1016/j.neurobiolaging.2020.11.010)
[Donaghy C, et al. ANCL associated with DNAJC5 mutations. Neurology. 2015](https://doi.org/10.1212/WNL.0000000000001720)
[Muñoz A, et al. Chaperone-based therapeutic strategies. Trends Pharmacol Sci. 2019](https://doi.org/10.1016/j.tips.2019.03.004)
[Tóth G, et al. Targeting Hsp70 and DNAJC5. Autophagy. 2019](https://doi.org/10.1080/15548627.2019.1633862)
[Johnson JN, et al. ER-mitochondria contact sites in neurodegeneration. Trends Cell Biol. 2019](https://doi.org/10.1016/j.tcb.2019.08.003)
[Rodríguez L, et al. Synaptic failure in alpha-synucleinopathies. Acta Neuropathol. 2020](https://doi.org/10.1007/s00401-020-02184-0)
[Moussa CE, et al. CSP in Alzheimer's disease. J Alzheimers Dis. 2019](https://doi.org/10.3233/JAD-190258)
[Kim Y, et al. CSP in synaptic vesicle recycling. Autophagy. 2018](https://doi.org/10.1080/15548627.2018.1489465)Mechanistic Role in Neurodegeneration
CSP in Synaptic Vesicle Cycling
The synaptic vesicle cycle is a highly coordinated process essential for neurotransmission. CSP plays critical roles at multiple stages:
Mermaid diagram (expand to render)
CSP in Protein Quality Control Network
CSP is an integral component of the neuronal protein quality control system:
Co-chaperone Function: The J-domain recruits Hsp70/Hsc70 to misfolded proteins
Substrate Recognition: The glycine-rich domain binds denatured proteins
Handoff to Degradation: CSP-Hsp70 complexes target irreversibly damaged proteins to:
- [Proteasome](/mechanisms/proteasome-degradation) (ubiquitin-dependent)
- [Lysosome](/mechanisms/autophagy-lysosome-neurodegeneration) (via chaperone-mediated autophagy)
CSP and Alpha-Synuclein Homeostasis
The relationship between CSP and [alpha-synuclein](/proteins/alpha-synuclein) is particularly relevant to [Parkinson's disease](/diseases/parkinsons-disease):
| Mechanism | Effect |
|-----------|--------|
| CSP deficiency | Enhanced α-syn oligomerization |
| CSP overexpression | Reduced α-syn aggregation |
| Autophagy regulation | CSP required for α-syn clearance |
| Hsp70 recruitment | CSP enhances Hsp70-mediated α-syn refolding |
CSP is enriched at mitochondria-associated membranes (MAMs), which are critical for:
- Calcium signaling: ER-mitochondria Ca²⁺ transfer
- Mitochondrial dynamics: Fission and fusion regulation
- Lipid transfer: Phospholipid metabolism
- Apoptosis regulation: Intrinsic pathway control
MAM dysfunction is implicated in both PD and AD, making CSP a key modulator of these disease processes.
Interaction Network
Protein-Protein Interactions
| Partner | Interaction Type | Functional Consequence |
|---------|-----------------|----------------------|
| Hsc70/Hspa8 | J-domain binding | Chaperone activity |
| Hsp40/DnaJB proteins | Co-chaperone complex | Client protein processing |
| Synaptotagmin | Calcium sensing | Synaptic vesicle fusion |
| SNARE proteins | Direct binding | Vesicle fusion |
| RyR | Calcium release | ER Ca²⁺ signaling |
| Mitochondrial proteins | Stress-induced | Oxidative stress protection |
| p62/SQSTM1 | Autophagy receptor | Selective autophagy |
| LC3/GABARAP | Autophagy | Lysosomal targeting |
Signaling Pathways
- cAMP/PKA: Phosphorylation of CSP serine residues
- Ca²⁺/Calmodulin: CSP-calmodulin interactions
- MAPK/ERK: Stress-responsive phosphorylation
- mTOR: Autophagy regulation of CSP levels
Clinical Perspectives
Biomarker Potential
CSP levels in cerebrospinal fluid (CSF) may serve as a biomarker:
- Reduced CSP: Associated with ANCL and PD
- CSF measurements: ELISA-based detection
- Correlation with disease: Under investigation
Diagnostic Applications
- Genetic testing: DNAJC5 sequencing for ANCL
- Protein analysis: Western blot of patient samples
- Functional assays: Chaperone activity measurements
Therapeutic Development
Chaperone-Based Approaches
| Strategy | Agent | Mechanism | Stage |
|----------|-------|-----------|-------|
| Pharmacological chaperone | 4-PBA | Protein stabilization | Preclinical |
| Hsp70 activator | Geranylgeranylacetone | Enhanced refolding | Preclinical |
| Autophagy inducer | Rapamycin | Enhanced clearance | Experimental |
| Autophagy activator | Trehalose | mTOR-independent | Preclinical |
Gene Therapy Approaches
- AAV9-CSP: Preclinical rescue of phenotype
- CRISPR-Cas9: Allele-specific editing for dominant mutations
- siRNA: Knockdown of dominant-negative mutants
Historical Context
The discovery of CSP as a neuronal protein dates to the early 1990s. Key milestones:
- 1992: Initial characterization of cysteine string protein
- 1997: Demonstration of J-domain function (Chamberlain & Burgoyne)
- 2008: Crystal structure of J-domain resolved
- 2012: CSP knockout mice generated (Sharma et al.)
- 2016: DNAJC5 mutations cause ANCL (Cadzow et al.)
- 2020: CSP-alpha-synuclein interaction in PD (García-Partida et al.)
Research Gaps and Future Directions
Structural biology: High-resolution structure of full-length CSP
Client protein repertoire: Comprehensive identification of CSP substrates
Therapeutic development: Clinical trials for pharmacological chaperones
Biomarkers: Validation of CSP as disease biomarker
Disease mechanisms: Elucidating CSP's role in specific neurodegenerative diseases